Xylo Bio
PrivateLast Round
Grant
Oct 28, 2024
Total Funding Raised
$9.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Xylo Bio operates in Healthcare & Life Sciences and is based in Boulder, Colorado. Its latest recorded funding round was a Grant round in October 2024.
Xylo Bio is a biotechnology company that develops targeted neuroplastogen therapies designed to rewire neural circuits and restore brain function for patients with psychiatric and neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xylo Bio Comparables
Compare Xylo Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Delix Therapeutics | 89% | |
| Gilgamesh Pharmaceuticals | 88% | |
| Kasvu Therapeutics | 86% |
For institutional investors. Book with your work email.
Xylo Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 28, 2024 | ||||
| Seed | Jun 3, 2024 | ||||
| Seed | Oct 1, 2022 | ||||
| Accelerator | Oct 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Xylo Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Startmate | Accelerator |
| Main Sequence Ventures | Seed |
| Gaingels | Seed |
| Lionheart Ventures | Seed |
| Negev Capital | Seed |
| Mystic Ventures | Seed |
| Palo Santo | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 32% MoM.
- Apr 16, 2026
Monthly visitors increased 135% MoM, reaching 8.6K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 15, 2026
XYLO highlights its program at the 9th Neuropsychiatric Drug Development Summit in Massachusetts from Sept 15th to 17th '26, where its CSO and co-founder, Dr. Samuel Banister, speaks.
For institutional investors. Book with your work email.
Xylo Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Xylo Bio's valuation, stock price, and market status.
Is Xylo Bio a public or private company?
Xylo Bio is a private company.
What is the current stock price of Xylo Bio?
Xylo Bio is a private company, so its shares have no public market price. Caplight tracks Xylo Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Xylo Bio worth (valuation)?
Valuation information for Xylo Bio is not publicly available.
Can I buy Xylo Bio stock?
Xylo Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Xylo Bio's last funding round?
Xylo Bio's most recent funding round was Grant on October 28, 2024.
Who are the main investors in Xylo Bio?
Key investors in Xylo Bio include Main Sequence Ventures, Possible Ventures, Tenmile.
Will Xylo Bio IPO soon?
No public IPO plans have been announced for Xylo Bio.
How can I track Xylo Bio secondary market activity?
Caplight tracks bids, offers, and trades in Xylo Bio's shares on secondary markets.